Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Gains from Sales and Divestitures (2019 - 2025)

Regenxbio has reported Gains from Sales and Divestitures over the past 5 years, most recently at $743000.0 for Q4 2025.

  • Quarterly results put Gains from Sales and Divestitures at $743000.0 for Q4 2025, up 88.1% from a year ago — trailing twelve months through Dec 2025 was $743000.0 (up 88.1% YoY), and the annual figure for FY2025 was $743000.0, up 88.1%.
  • Gains from Sales and Divestitures for Q4 2025 was $743000.0 at Regenxbio, up from $732000.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for RGNX hit a ceiling of $743000.0 in Q4 2025 and a floor of $68.0 in Q4 2022.
  • Median Gains from Sales and Divestitures over the past 4 years was $252000.0 (2023), compared with a mean of $306191.8.
  • Biggest five-year swings in Gains from Sales and Divestitures: surged 269017.65% in 2023 and later surged 67.04% in 2025.
  • Regenxbio's Gains from Sales and Divestitures stood at $68.0 in 2022, then surged by 269017.65% to $183000.0 in 2023, then soared by 115.85% to $395000.0 in 2024, then surged by 88.1% to $743000.0 in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $743000.0 (Q4 2025), $732000.0 (Q3 2025), and $598000.0 (Q2 2025) per Business Quant data.